BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 36765737)

  • 1. Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer.
    Liu J; Mroczek M; Mach A; Stępień M; Aplas A; Pronobis-Szczylik B; Bukowski S; Mielczarek M; Gajewska E; Topolski P; Król ZJ; Szyda J; Dobosz P
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
    Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of PALB2-associated breast cancers.
    Lee JEA; Li N; Rowley SM; Cheasley D; Zethoven M; McInerny S; Gorringe KL; James PA; Campbell IG
    J Pathol; 2018 May; 245(1):53-60. PubMed ID: 29431189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients.
    Zong H; Zhang J; Xu Z; Pan JN; Wang R; Han J; Jiang M; Ren R; Zang L; Wang H; Cao WM
    J Cancer; 2022; 13(4):1119-1129. PubMed ID: 35281878
    [No Abstract]   [Full Text] [Related]  

  • 5. Pan-cancer landscape of homologous recombination deficiency.
    Nguyen L; W M Martens J; Van Hoeck A; Cuppen E
    Nat Commun; 2020 Nov; 11(1):5584. PubMed ID: 33149131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
    BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.
    Jiao Y; Yonescu R; Offerhaus GJ; Klimstra DS; Maitra A; Eshleman JR; Herman JG; Poh W; Pelosof L; Wolfgang CL; Vogelstein B; Kinzler KW; Hruban RH; Papadopoulos N; Wood LD
    J Pathol; 2014 Mar; 232(4):428-35. PubMed ID: 24293293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
    Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
    Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
    Park D; Shakya R; Koivisto C; Pitarresi JR; Szabolcs M; Kladney R; Hadjis A; Mace TA; Ludwig T
    PLoS One; 2019; 14(12):e0226714. PubMed ID: 31877165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
    Zhen DB; Rabe KG; Gallinger S; Syngal S; Schwartz AG; Goggins MG; Hruban RH; Cote ML; McWilliams RR; Roberts NJ; Cannon-Albright LA; Li D; Moyes K; Wenstrup RJ; Hartman AR; Seminara D; Klein AP; Petersen GM
    Genet Med; 2015 Jul; 17(7):569-77. PubMed ID: 25356972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent Mutations in
    Łukomska A; Menkiszak J; Gronwald J; Tomiczek-Szwiec J; Szwiec M; Jasiówka M; Blecharz P; Kluz T; Stawicka-Niełacna M; Mądry R; Białkowska K; Prajzendanc K; Kluźniak W; Cybulski C; Dębniak T; Huzarski T; Tołoczko-Grabarek A; Byrski T; Baszuk P; Narod SA; Lubiński J; Jakubowska A
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian Cancer-Specific
    Schouten PC; Richters L; Vis DJ; Kommoss S; van Dijk E; Ernst C; Kluin RJC; Marmé F; Lips EH; Schmidt S; Scheerman E; Prieske K; van Deurzen CHM; Burges A; Ewing-Graham PC; Dietrich D; Jager A; de Gregorio N; Hauke J; du Bois A; Nederlof PM; Wessels LF; Hahnen E; Harter P; Linn SC; Schmutzler RK
    Clin Cancer Res; 2021 Dec; 27(23):6559-6569. PubMed ID: 34593530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EUS-based Pancreatic Cancer Surveillance in
    Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
    Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.
    Mekonnen N; Yang H; Shin YK
    Front Oncol; 2022; 12():880643. PubMed ID: 35785170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine Neoplasms Associated with Germline Pathogenic Variants in the Homologous Recombination Pathway.
    Szybowska M; Mete O; Weber E; Silver J; Kim RH
    Endocr Pathol; 2019 Sep; 30(3):237-245. PubMed ID: 30772928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer.
    Cicenas J; Kvederaviciute K; Meskinyte I; Meskinyte-Kausiliene E; Skeberdyte A; Cicenas J
    Cancers (Basel); 2017 Apr; 9(5):. PubMed ID: 28452926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.